Sapporo Medical University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Sapporo Japan (1945)

Organization Overview

First Clinical Trial
2009
NCT01010022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Emeritus Professor, Sapporo Medical University | Emeritus Professor Sapporo Medical University; CEO, Otaru City Hospitals, Hokkaido, Japan | Sapporo Medical University, School of Medicine

Active Ingredients

Drugs in Phase 4 Trials (1)

dexmedetomidine (precedex) (1 trial)

Drugs in Phase 3 Trials (1)

hydroxyethyl starch (voluven) (2 trials)

Drugs in Phase 2 Trials (3)

desflurane (suprane) (1 trial)

encenicline (1 trial)

sevoflurane (ultane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Hemorrhage (Phase 3)

Hypovolemia (Phase 3)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5